Immunome Inc. 4

Immunome Inc. CTO Philip Tsai received 38,250 RSUs of common stock and 76,500 employee stock options at a $22.01 exercise price as part of an equity compensation grant.

On July 23, 2026, Immunome Inc. Chief Technical Officer Philip Tsai received an equity compensation package consisting of 38,250 restricted stock units (RSUs) of common stock and an option grant for 76,500 shares of common stock at an exercise price of $22.01 per share. The RSUs represent a contingent right to receive common shares, vesting 25% annually on each anniversary of the grant date, assuming continued service, which will increase his direct share ownership as they vest. The stock options vest 25% on July 23, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 months, also contingent on continued service, and are exercisable through July 22, 2036. Following these awards, Tsai holds 81,550 shares of common stock directly (after reflecting the RSU grant), plus the newly awarded 76,500 stock options, materially increasing his equity-linked exposure to the company through primarily routine compensation-related grants rather than open-market purchases.

Filing Facts

CIK

1472012

Ticker

IMNM

Form

4

Source Type

fda

Accession

0002026600-26-000002

Alert Tier

5